BS

Bhavika Saumilbhai Shah

Director Additional Director DIN 10070361
DIN 10070361 First appointment Mar 2023 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 1 historical roles
Total affiliations 1 Since Mar 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Bhavika Saumilbhai Shah

Data last updated:

Bhavika Saumilbhai Shah was an Additional Director at Sabwell Pharmaceuticals Private Limited (2023). The company operates in Pharma.

DIN 10070361
Primary Designation Additional Director
Industry Pharma
First Appointment 01 Mar 2023

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Additional Director01 Mar 20232023₹37.3 Lakh (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Sabwell Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Bhavika Saumilbhai Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bhavika Saumilbhai Shah

Bhavika Saumilbhai Shah was first appointed on 01 Mar 2023 as Additional Director at Sabwell Pharmaceuticals Private Limited.

Bhavika Saumilbhai Shah held 1 earlier board appointment: Sabwell Pharmaceuticals Private Limited (Additional Director, 01 Mar 2023 to 03 Oct 2023).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available